EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

The effect of icotinib or apatinib on the pharmacokinetic profile of oxycodone in rats and the underlying mechanism

Qi Zhou, Feng Ye, Zhize Ye, Nanyong Gao, Qihui Kong, Xiaoqin Hu, Jianchang Qian, Bin Wu

PeerJ · 2023

DOI: 10.7717/peerj.16601 ↗

At a glance

Journal article in PeerJ, 2023. Written by Qi Zhou and 7 co-authors. Institution: Wenzhou Medical University, Wenzhou, China. Major MEDLINE topics: Oxycodone, Tandem Mass Spectrometry. Cited 2 times so far (Crossref); 37 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Key Research and Development Program of China, National Natural Science Foundation of China, Natural Science Foundation of Zhejiang Province.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

This study aimed to investigate the interactions between icotinib/apatinib and oxycodone in rats and to unveil the underlying mechanism. An ultra-performance liquid chromatography–tandem mass spectrometry (UPLC-MS/MS) method was developed and validated to determine oxycodone and its demethylated metabolite simultaneously. In vivo , Sprague–Dawley (SD) male rats were administered oxycodone with or without icotinib or apatinib. Blood samples were collected and subjected to UPLC-MS/MS analysis. An enzyme incubation assay was performed to investigate the mechanism of drug–drug interaction using both rat and human liver microsomes (RLM and HLM). The results showed that icotinib markedly increased the AUC (0–t) and AUC (0–∞) of oxycodone but decreased the CL z/F . The C max of oxycodone increased significantly upon co-administration of apatinib. In vitro , the K m value of oxycodone metabolism was 101.7 ± 5.40 μM and 529.6 ± 19.60 μM in RLMs and HLMs, respectively. Icotinib and apatinib inhibited the disposition of oxycodone, with a mixed mechanism in RLM (IC 50 = 3.29 ± 0.090 μM and 0.95 ± 0.88 μM, respectively) and a competitive and mixed mechanism in HLM (IC 50 = 22.34 ± 0.81 μM and 0.48 ± 0.05 μM, respectively). In conclusion, both icotinib and apatinib inhibit the metabolism of oxycodone in vitro and in vivo . Therefore, the dose of oxycodone should be reconsidered when co-administered with icotinib or apatinib.

Subjects

MeSH terms (MEDLINE)

OxycodoneTandem Mass SpectrometryRatsMaleHumansAnimalsRats, Sprague-DawleyChromatography, LiquidChromatography, High Pressure LiquidPyridinesQuinazolinesCrown Ethers

Author keywords

ApatinibIcotinibInteractionOxycodoneUPLC-MS/MS

Substances

OxycodoneapatinibPyridinesicotinibQuinazolinesCrown Ethers

Authors and institutions

  • Wenzhou Medical University, Wenzhou, China.
  • Shaoxing People's Hospital, Shaoxing, China.
  • The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.

Funding

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Natural Science Foundation of Zhejiang Province
  • Wenzhou Municipal Science and Technology Bureau

Cite

APA

Zhou, Q., Ye, F., Ye, Z., Gao, N., Kong, Q., Hu, X., Qian, J., & Wu, B. (2023). The effect of icotinib or apatinib on the pharmacokinetic profile of oxycodone in rats and the underlying mechanism. PeerJ. https://doi.org/10.7717/peerj.16601

Vancouver

Zhou Q, Ye F, Ye Z, Gao N, Kong Q, Hu X, et al. The effect of icotinib or apatinib on the pharmacokinetic profile of oxycodone in rats and the underlying mechanism. PeerJ. 2023. doi:10.7717/peerj.16601

BibTeX
@article{Zhou2023,
  author = {Zhou, Qi and Ye, Feng and Ye, Zhize and Gao, Nanyong and Kong, Qihui and Hu, Xiaoqin and Qian, Jianchang and Wu, Bin},
  title = {The effect of icotinib or apatinib on the pharmacokinetic profile of oxycodone in rats and the underlying mechanism},
  journal = {PeerJ},
  year = {2023},
  doi = {10.7717/peerj.16601}
}
Start for free →